FDA Grants Accelerated Approval for First Plasmid DNA-based Immunotherapy for Recurrent Respiratory Papillomatosis

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP). This rare disease, caused by human papillomavirus (HPV), leads to wart-like growths in the airways. The approval offers a new therapeutic option targeting the root cause of RRP.